Komlos D
Clarivate, Philadelphia, Pennsylvania, USA.
Drugs Today (Barc). 2020 Dec;56(12):795-802. doi: 10.1358/dot.2020.56.12.3241213.
This year's annual conference of the Food and Drug Law Institute (FDLI) drew more than 700 attendees, including over 200 from the U.S. Food and Drug Administration (FDA), and featured 93 speakers. Despite being held virtually for the first time, the event offered a full agenda comprising breakout sessions, award presentations, and opportunities for networking that included postsession roundtable discussions and a sponsor virtual exhibit hall. Not surprisingly, the reality of the COVID-19 public health emergency was a recurrent and emphasized theme throughout the 3 days of the conference. This report summarizes several of the 29 breakout sessions from the event.
今年的食品药品法律协会（FDLI）年会吸引了700多名与会者，其中包括200多名来自美国食品药品监督管理局（FDA）的人员，并有93位演讲者。尽管该活动首次以线上形式举办，但议程安排充实，包括分组会议、颁奖仪式以及交流机会，其中交流机会涵盖会后圆桌讨论和赞助商虚拟展厅。不出所料，在为期3天的会议中，新冠疫情公共卫生紧急状况这一现实是反复出现且重点强调的主题。本报告总结了该活动29场分组会议中的几场会议内容。
